Pearl River Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Pearl River Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-25,637	Closed	-$294K	–	497
2022 Q4	$294K	Buy	25,637 +5,114	+25%	+$63.8K	0.05%	417
2022 Q3	$259K	Buy	+20,523	New	+$264K	0.05%	398
2022 Q2	–	Sell	-45,155	Closed	-$734K	–	443
2022 Q1	$734K	Buy	45,155 +11,275	+33%	+$181K	0.2%	156
2021 Q4	$469K	Buy	33,880 +4,390	+15%	+$58.1K	0.13%	230
2021 Q3	$424K	Sell	29,490 -30,939	-51%	-$488K	0.12%	251
2021 Q2	$955K	Buy	+60,429	New	+$821K	0.26%	119
2020 Q1	–	Sell	-10,989	Closed	-$38K	–	514
2019 Q4	$38K	Buy	+10,989	New	+$27.6K	0.01%	509

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Pearl River Capital's BCRX Position: Q1 2023 in Review

Pearl River Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2023, closing a stake of 25,637 shares — an estimated $294K sold.

Pearl River Capital first reported a position in BCRX in Q4 2019 and held it in 7 quarters. The position peaked at $955K in Q2 2021. 241 funds tracked by Wall St. Rank hold BCRX as of Q1 2023.

Pearl River Capital reported no remaining BioCryst Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Pearl River Capital sold 25,637 BioCryst Pharmaceuticals shares in Q1 2023, an estimated $294K.
Pearl River Capital first reported a position in BioCryst Pharmaceuticals in Q4 2019 and held it in 7 quarters.
Pearl River Capital's BioCryst Pharmaceuticals position peaked at $955K in Q2 2021.
241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2023.

Based on Pearl River Capital's 13F filing for Q1 2023, filed 12 May 2023.